A Phase I, Randomised, Open-Label, Single and Multiple Ascending Dose (Twice-Daily), Incomplete Block, Cross-Over Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide Administered by Inhalation in Healthy Chinese Subjects

Trial Profile

A Phase I, Randomised, Open-Label, Single and Multiple Ascending Dose (Twice-Daily), Incomplete Block, Cross-Over Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide Administered by Inhalation in Healthy Chinese Subjects

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs Aclidinium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Jan 2018 Planned End Date changed from 24 Jan 2018 to 16 Apr 2018.
    • 10 Jan 2018 Planned primary completion date changed from 24 Jan 2018 to 16 Apr 2018.
    • 10 Jan 2018 Planned initiation date changed from 22 Dec 2017 to 14 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top